The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

The impact of Hurricane Helene has led to a temporary supply disruption at the Baxter facility in Marion, North Carolina. The facility manufactures a significant portion of IV solutions, irrigation ...

The Food and Drug Administration (FDA) has granted Fast Track designation to liafensine (DB104) for patients with treatment-resistant depression (TRD).

Importantly, the CDC data remains preliminary and could change because state data lags as coroners and medical examiners conclude death investigations.

HealthDay News — Implementation of a tobacco-free generation could substantially reduce global lung cancer mortality, according to a study published in the October issue of The Lancet Public Health.

HealthDay News — Artificial intelligence (AI) scores may be able to estimate the risk for future breast cancer and lead to earlier diagnosis, according to a study published online October 3 in JAMA ...

HealthDay News — Liposomal bupivacaine is not associated with significant improvement in postoperative pain or function or hospital length of stay following hip hemiarthroplasty for a femoral neck ...

HealthDay News — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to survodutide for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate or ...

The Healgen at-home test is the first OTC test for influenza detection to be granted marketing authorization outside of an ...

Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for sepiapterin as a treatment for pediatric and adult patients living with phenylketonuria (PKU).